FDA approves revolutionary Skinvive by Juvederm

The one-of-its-kind treatment for improving skin smoothness has been approved by the FDA. Skinvive by Juvederm is the first hyaluronic acid intradermal microdroplet injection. It has been approved for usage in adults above 21 years of age. The injectable gel contains lidocaine, a local anaesthetic that works to improve skin quality and lower the discomfort of the treatment. The drug works by increasing hydration and smoothing the fine lines. The product has been approved for use in all Fitzpatrick skin types I to VI. An inclusive study was conducted to get this approval. In cosmetic and aesthetic dermatology, hydration is key to skin quality enhancement. And Skinvive works beneath the skin surface to increase hydration, thus enhancing skin quality and smoothness.

Alexiades, a board-certified dermatologist in the US and European Union, as well as the lead investigator for Skinvive published about the drug’s efficacy and safety. This authored study has been published in the Dermatologic Surgery Journal.

Allergan Aesthetics, an AbbVie company, estimated Skinvive by Juvederm’s availability in six months. While sharing the commercial estimates, the press release also shared the following study results based on the trials that led to the FDA approval.

Facial skin healthiness:

• 38% baseline satisfaction

• 83% post-treatment satisfaction

Facial skin hydration:

• 24% baseline satisfaction

• 72% post-treatment satisfaction

Facial skin refreshed ness:

• 16% baseline satisfaction

• 69% post-treatment satisfaction